Analysis of real-world treatment patterns in a matched rheumatology population that continued innovator infliximab therapy or switched to biosimilar infliximab

PURPOSE: This study compared treatment patterns of Turkish patients with a diagnosis of rheumatoid arthritis (RA) who were treated with innovator Remicade(®) (infliximab [IFX]) and either continued IFX or switched to CT-P13. MATERIALS AND METHODS: Adult RA patients with ≥1 IFX claim were identified...

Descripción completa

Detalles Bibliográficos
Autores principales: Yazici, Yusuf, Xie, Lin, Ogbomo, Adesuwa, Ellis, Lorie A, Goyal, Kavitha, Teeple, Amanda, Simsek, Ismail
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6207267/
https://www.ncbi.nlm.nih.gov/pubmed/30498332
http://dx.doi.org/10.2147/BTT.S172337

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6207267/
https://www.ncbi.nlm.nih.gov/pubmed/30498332
http://dx.doi.org/10.2147/BTT.S172337

Ejemplares similares